Compare Lamb Weston Holdings Inc (LW) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lamb Weston Holdings Inc vs Novavax Inc — how do they compare? Lamb Weston Holdings Inc trades at $47.77 (market cap $6.81B), while Novavax Inc trades at $12.73 (market cap $1.82B). The key difference: Lamb Weston Holdings Inc is far larger — about 3.7× Novavax Inc's market cap, and Lamb Weston Holdings Inc pays a 3.07% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lamb Weston Holdings Inc for 66 Days and Novavax Inc for 59 Days on average.
| LW | NVAX | |
|---|---|---|
Market Cap | $6.81B | $1.82B |
Volume | 4,638,686 | 6,198,505 |
Sector | Consumer Staples | Health |
52-Week High | $66.57 | $12.56 |
52-Week Low | $38.48 | $6.22 |
Typical Hold Time | 66 Days | 59 Days |
Enterprise Value | $10.61B | $1.39B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lamb Weston (LW) trades at $47.87, down 0.46% on the day, with a bullish technical signal supported by moving averages. The company shows consistent earnings beats in recent quarters, with Q3 2026 EPS of $0.75 exceeding expectations of $0.587. Revenue reached $6.45 billion in 2025, though net income margin declined to 3.85%. Analyst consensus price target stands at $53.71, representing 12% upside potential from current levels.
The stock presents a mixed outlook with strong technical momentum and earnings consistency offset by margin compression and elevated valuation at 27x P/E. Key risks include competitive pressures in the food industry and ongoing margin challenges. Institutional sentiment leans cautious with 63% hold ratings, suggesting limited near-term catalysts despite the technical bullish setup.
Novavax (NVAX) trades at $12.75, up 13.64% with strong technical momentum and bullish moving averages. The company shows mixed fundamentals with revenue of $1.12B in 2025 and positive net income of $440.30M, though 2026 projections indicate a return to losses. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with high volatility. Opportunities include partnership-driven growth and vaccine demand, but risks involve consistent profitability challenges, high debt-to-asset ratios, and competitive pressures. Analyst sentiment is predominantly bullish (73.9% buy ratings), yet investors should weigh the company's transition phase against financial stability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
